Neurodegeneration is a condition in which the structure and/or function of neurons in the central nervous system (CNS) is impaired. Neurodegenerative diseases are the result of a gradual decline in neuronal function due to a number of complex causes, including genetic, physiological, and environmental factors. Neurodegenerative diseases are characterized by a progressive loss of motor and cognitive function, due to the breakdown of neurons in the brain and spinal cord. Common examples of neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). Neurodegenerative diseases can be caused by a variety of factors, including genetic abnormalities, environmental insults such as head trauma, metabolic changes, or exposure to certain neurotoxins. The underlying mechanisms of these diseases remain unknown, and current research is focused on elucidating the neurodegenerative pathways involved. In many cases, scientists believe a combination of genetic and environmental factors play a role in the onset of neurodegenerative diseases. The symptoms of neurodegenerative diseases vary, but commonly include problems with memory, spatial orientation, language comprehension, and problem-solving abilities. In advanced stages, these cognitive problems can progress to include difficulty in writing, speaking, and even walking. While there is currently no cure for neurodegenerative diseases, treatments are available to help manage symptoms and slow the progression of the disease. The importance of ongoing research on neurodegeneration cannot be overstated. The better we understand the mechanisms of neurodegenerative diseases, the better we will be able to develop treatments or even find ways to prevent or delay the onset of these potentially devastating conditions.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States